amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte
Amorcyte Logo Cell Therapy Solutions for Cardiovascular Disease amorcyte home amorcyte contact us amorcyte
amorcyte amorcyte
amorcyte amorcyte
amorcyte amorcyte
amorcyte
amorcyte
amorcyte
AMORCYTE STEM CELL THERAPY DEMONSTRATES CLINICALLY SIGNIFICANT REPERFUSION IN SEVERE HEART ATTACK PATIENTS
American Heart Journal Publication Establishes Achievement of Threshold Dose
amorcyte
amorcyte
Allendale, NJ, (December 21, 2010)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE REPORTS PHASE I RESULTS OF AMR-001 TO IMPROVE RECOVERY FROM SEVERE HEART ATTACK AT ACC ANNUAL SCIENTIFIC SESSION
First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion
amorcyte
amorcyte
Orlando, Fla, (March 30, 2009)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
After Heart Attack, Bone Marrow Stem Cells Increase Blood Flow Within Heart

amorcyte
amorcyte
Orlando, Fla, (March 30, 2009)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE COMPLETES PHASE I TRIAL OF STEM CELL THERAPY FOR ACUTE MYOCARDIAL INFARCTION
amorcyte
(Amorcyte) announced today the completion of the phase I clinical trial of its lead product, AMR-001.
amorcyte
HACKENSACK, New Jersey - (April 1, 2008)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE CARDIAC CELL THERAPY TRIAL COMPLETES SECOND OF FOUR PHASES
Stem cell therapy trial picks up pace with three sites now accruing patients
amorcyte
amorcyte
HACKENSACK, New Jersey - (May 8, 2007)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
PAUL HARVEY, CELEBRATED NEWS COMMENTATOR, DISCUSSED THE AMORCYTE-FUNDED STUDY IN HIS FRIDAY MORNING BROADCAST
Referring to the study as “rescuing heart attack victims by regenerating heart muscle with stem cell therapy”.
amorcyte
amorcyte
HACKENSACK, New Jersey - (April 13, 2007)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE CARDIAC CELL THERAPY TRIAL PASSES FIRST STAGE AND OPENS TWO NEW SITES
Stem cell therapy trial proceeds to next stage and opens in two new clinical centers
amorcyte
HACKENSACK, New Jersey - (January 2, 2007)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE SECURES ADDITIONAL FUNDING TO EXPAND CLINICAL PROGRAM IN CARDIOVASCULAR THERAPY
PA Early Stage joins Colt Ventures in expanding Amorcyte’s product program
amorcyte
Hackensack, New Jersey (PRWEB) October 23, 2006
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE SECURES PRODUCTION CAPACITY FOR LEAD CELL THERAPY PRODUCT
amorcyte
Progenitor Cell Therapy LLC is retained to develop and manufacture AMR-001.
amorcyte
Hackensack, NJ (PRWEB) June 28, 2006
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE CLOSES $4.2 MILLION SERIES A FINANCING
amorcyte
Financing to fund 40-patient cardiovascular cell therapy trial
amorcyte
HACKENSACK, New Jersey - (June 19, 2006)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE, INC OPENS CELL THERAPY TRIAL FOR CARDIOVASCULAR DISEASE AT EMORY UNIVERSITY
amorcyte
Initial Study to Focus on Safety, Efficacy, and Mechanism of Action
amorcyte
HACKENSACK, New Jersey - (June 5, 2006)
amorcyte
amorcytemore
amorcyte amorcyte
amorcyte


amorcyte
amorcyte amorcyte
amorcyte amorcyte
amorcyte amorcyte amorcyte
Back to Top
amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte